Danish biotech and drug companies are among the best in Europe when it comes to the number of candidate drugs under development, according to a new study.
Nordic Life Sciences sector study 2014, by Ernst & Young, concludes that Denmark has the largest pipeline of drugs undergoing clinical trials in Europe relative to its size. Last year, the country had a total of 107 candidates in clinical phase I, II and III.
“One of the reasons why Denmark’s pipeline of drug development is so strong is the high number of innovative biotech companies. Denmark has more than 160 biotech firms which is about equivalent to a country like France with a ten times larger population”, Rasmus Beedholm-Ebsen says and continues: “Even though many of the Danish biotech companies are relatively small, it is important to have a critical mass of research companies in the sector in order to get drugs into clinical development. Furthermore, it is crucial that the strong position in drug development is backed by a proven ability to take drug candidates into preclinical and clinical development and onto the market,” commented Rasmus Beedholm-Ebsen, Ph.D. and Project Manager at Invest in Denmark.
Source & image: Invest in Denmark
